Nifty
:
22535.85
Sensex
:
74227.08
374.25 (1.69%)
1089.18 (1.49%)
Menu
Nifty
Sensex
:
:
22535.85
74227.08
374.25 (1.69%)
1089.18 (1.49%)

Syngene International Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 539268 | NSE: SYNGENE

NSE BSE
746.35
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  748.65
  •  757.80
  •  740.35
  •  746.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  535034
  •  3992.71
  •  960.60
  •  607.65

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 27,976.32
  • 55.79
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 27,615.32
  • 0.18%
  • 6.18

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 52.74%
  • 0.50%
  • 5.59%
  • FII
  • DII
  • Others
  • 20.65%
  • 18.64%
  • 1.88%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.05
  • 11.64
  • 10.24

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.07
  • 10.95
  • 6.50

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.30
  • 4.36
  • 8.82

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 56.52
  • 58.15
  • 58.32

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.44
  • 7.81
  • 7.42

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.61
  • 28.74
  • 27.97

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
12.71
13.4
17.02
21.25
P/E Ratio
72.11
68.38
53.85
43.13
Revenue
3489
3802
4461
5212
EBITDA
1070
1115
1362
1639
Net Income
510
547
688
854
ROA
8.5
8.9
9.6
10.7
P/B Ratio
8.65
7.81
6.89
5.94
ROE
12.95
12.22
13.31
14.41
FCFF
602.8
348.14
496.69
642.03
FCFF Yield
1.67
0.96
1.37
1.78

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
943.70
853.50
10.57%
891.00
910.10
-2.10%
789.70
808.10
-2.28%
916.90
994.40
-7.79%
Expenses
661.80
622.00
6.40%
650.50
656.00
-0.84%
619.90
596.20
3.98%
600.00
680.30
-11.80%
EBITDA
281.90
231.50
21.77%
240.50
254.10
-5.35%
169.80
211.90
-19.87%
316.90
314.10
0.89%
EBIDTM
29.87%
27.12%
26.99%
27.92%
21.50%
26.22%
34.56%
31.59%
Other Income
20.00
29.30
-31.74%
20.80
21.60
-3.70%
18.10
23.60
-23.31%
16.10
22.80
-29.39%
Interest
12.40
10.80
14.81%
13.10
13.00
0.77%
11.70
10.50
11.43%
12.90
10.40
24.04%
Depreciation
108.70
108.10
0.56%
110.90
104.60
6.02%
106.90
102.10
4.70%
111.10
95.60
16.21%
PBT
180.80
138.20
30.82%
137.30
150.70
-8.89%
101.30
122.90
-17.58%
209.00
230.90
-9.48%
Tax
49.70
26.70
86.14%
31.20
34.20
-8.77%
25.60
29.50
-13.22%
20.40
52.20
-60.92%
PAT
131.10
111.50
17.58%
106.10
116.50
-8.93%
75.70
93.40
-18.95%
188.60
178.70
5.54%
PATM
13.89%
13.06%
11.91%
12.80%
9.59%
11.56%
20.57%
17.97%
EPS
3.26
2.77
17.69%
2.64
2.90
-8.97%
1.88
2.32
-18.97%
4.69
4.45
5.39%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
3,289.60
3,203.10
3,193.50
2,601.40
2,179.40
2,011.90
1,825.60
1,423.10
1,200.90
1,107.00
859.90
Net Sales Growth
-1.30%
0.30%
22.76%
19.36%
8.33%
10.20%
28.28%
18.50%
8.48%
28.74%
 
Cost Of Goods Sold
858.70
56.60
-42.00
-21.60
526.50
519.40
531.30
381.70
321.80
310.40
239.00
Gross Profit
2,430.90
3,146.50
3,235.50
2,623.00
1,652.90
1,492.50
1,294.30
1,041.40
879.10
796.60
620.90
GP Margin
73.90%
98.23%
101.32%
100.83%
75.84%
74.18%
70.90%
73.18%
73.20%
71.96%
72.21%
Total Expenditure
2,387.80
2,324.40
2,260.90
1,863.60
1,528.10
1,409.70
1,291.10
1,033.00
816.20
726.60
578.80
Power & Fuel Cost
-
54.20
69.20
64.40
57.40
45.80
41.30
34.70
30.40
30.80
27.50
% Of Sales
-
1.69%
2.17%
2.48%
2.63%
2.28%
2.26%
2.44%
2.53%
2.78%
3.20%
Employee Cost
-
761.20
812.20
697.80
641.50
572.20
465.40
376.90
308.60
249.30
201.90
% Of Sales
-
23.76%
25.43%
26.82%
29.43%
28.44%
25.49%
26.48%
25.70%
22.52%
23.48%
Manufacturing Exp.
-
1,031.10
1,078.80
913.70
130.00
103.70
85.70
66.70
55.50
29.50
21.40
% Of Sales
-
32.19%
33.78%
35.12%
5.96%
5.15%
4.69%
4.69%
4.62%
2.66%
2.49%
General & Admin Exp.
-
314.80
250.40
168.70
136.10
140.60
146.00
142.40
83.40
64.80
54.30
% Of Sales
-
9.83%
7.84%
6.48%
6.24%
6.99%
8.00%
10.01%
6.94%
5.85%
6.31%
Selling & Distn. Exp.
-
16.20
18.00
11.80
6.10
11.10
7.70
6.10
6.30
4.80
3.80
% Of Sales
-
0.51%
0.56%
0.45%
0.28%
0.55%
0.42%
0.43%
0.52%
0.43%
0.44%
Miscellaneous Exp.
-
90.30
74.30
28.80
30.50
16.90
13.70
24.50
10.20
37.00
3.80
% Of Sales
-
2.82%
2.33%
1.11%
1.40%
0.84%
0.75%
1.72%
0.85%
3.34%
3.59%
EBITDA
901.80
878.70
932.60
737.80
651.30
602.20
534.50
390.10
384.70
380.40
281.10
EBITDA Margin
27.41%
27.43%
29.20%
28.36%
29.88%
29.93%
29.28%
27.41%
32.03%
34.36%
32.69%
Other Income
72.50
88.00
72.60
108.40
83.30
96.10
76.20
136.10
93.60
6.30
11.70
Interest
29.60
29.50
45.20
24.10
27.70
34.60
32.30
22.70
17.50
8.40
7.90
Depreciation
373.40
368.80
359.10
309.70
274.50
219.30
164.20
131.40
114.30
97.30
81.40
PBT
603.30
568.40
600.90
512.40
432.40
444.40
414.20
372.10
346.50
281.00
203.50
Tax
119.90
90.80
127.90
87.90
63.70
104.20
83.50
67.00
59.20
40.20
28.50
Tax Rate
19.87%
16.29%
21.28%
18.25%
13.63%
20.21%
20.16%
18.01%
17.09%
14.31%
14.00%
PAT
483.40
466.50
473.00
393.80
403.70
411.50
330.70
305.10
287.30
240.80
175.00
PAT before Minority Interest
483.40
466.50
473.00
393.80
403.70
411.50
330.70
305.10
287.30
240.80
175.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
14.69%
14.56%
14.81%
15.14%
18.52%
20.45%
18.11%
21.44%
23.92%
21.75%
20.35%
PAT Growth
3.80%
-1.37%
20.11%
-2.45%
-1.90%
24.43%
8.39%
6.20%
19.31%
37.60%
 
EPS
12.01
11.59
11.75
9.78
10.03
10.22
8.22
7.58
7.14
5.98
4.35

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
4,191.50
3,618.90
3,292.00
2,818.30
2,174.10
1,967.20
1,720.10
1,413.10
1,024.70
844.90
Share Capital
402.00
401.40
400.80
400.00
400.00
200.00
200.00
200.00
200.00
199.10
Total Reserves
3,772.10
3,154.70
2,804.20
2,341.40
1,735.20
1,739.20
1,491.90
1,187.90
805.80
633.90
Non-Current Liabilities
494.00
780.40
972.20
840.10
325.20
515.00
612.60
697.70
725.10
101.40
Secured Loans
100.00
489.00
531.50
512.40
0.00
346.60
568.80
689.80
725.20
18.60
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
16.70
0.00
0.00
0.00
Long Term Provisions
38.10
41.70
34.40
52.00
40.90
37.40
29.00
19.90
18.10
13.20
Current Liabilities
1,098.60
1,157.20
1,231.50
1,130.40
1,540.00
1,128.60
783.30
600.30
534.00
475.20
Trade Payables
254.00
260.40
235.30
239.10
222.80
223.50
203.40
102.50
74.40
69.20
Other Current Liabilities
689.00
749.70
655.90
571.60
955.10
677.60
475.60
379.40
276.40
260.20
Short Term Borrowings
41.70
86.30
258.10
259.90
308.90
190.70
78.10
97.20
165.80
136.40
Short Term Provisions
113.90
60.80
82.20
59.80
53.20
36.80
26.20
21.20
17.40
9.40
Total Liabilities
5,784.10
5,556.50
5,495.70
4,788.80
4,039.30
3,610.80
3,116.00
2,711.10
2,283.80
1,421.50
Net Block
2,276.80
2,211.80
2,354.30
2,163.40
1,983.70
1,336.80
1,030.40
810.40
580.20
503.30
Gross Block
4,293.70
3,993.60
3,882.50
3,404.40
2,967.40
2,121.20
1,660.70
1,331.90
1,111.40
938.00
Accumulated Depreciation
2,016.90
1,781.80
1,528.20
1,241.00
983.70
784.40
630.30
521.50
531.20
434.70
Non Current Assets
3,932.30
2,884.10
3,292.10
2,987.80
2,427.90
1,848.20
1,396.70
1,187.00
949.10
835.70
Capital Work in Progress
759.60
126.20
346.40
237.20
234.10
273.70
155.40
174.90
236.80
105.10
Non Current Investment
435.00
116.40
270.60
316.60
74.30
40.30
0.30
0.00
0.00
0.00
Long Term Loans & Adv.
230.30
164.50
150.70
115.10
107.80
121.90
94.90
91.20
71.70
113.40
Other Non Current Assets
189.50
217.10
131.60
155.50
28.00
75.50
115.70
110.50
60.40
113.90
Current Assets
1,851.80
2,355.30
2,203.60
1,801.00
1,611.40
1,762.60
1,719.30
1,524.10
1,334.70
585.80
Current Investments
492.60
824.40
763.80
423.30
738.40
716.00
157.70
540.40
276.60
146.00
Inventories
234.00
332.80
179.40
59.60
25.20
43.40
86.00
32.20
37.70
38.40
Sundry Debtors
427.50
484.40
508.20
474.40
398.20
338.70
266.80
198.70
185.20
179.90
Cash & Bank
528.20
509.30
515.10
638.20
280.30
435.40
966.50
527.30
719.90
115.70
Other Current Assets
169.50
140.10
157.00
173.90
169.30
229.10
242.30
225.50
115.30
105.80
Short Term Loans & Adv.
58.20
64.30
80.10
31.60
68.70
3.90
5.90
23.90
25.10
28.90
Net Current Assets
753.20
1,198.10
972.10
670.60
71.40
634.00
936.00
923.80
800.70
110.60
Total Assets
5,784.10
5,239.40
5,495.70
4,788.80
4,039.30
3,610.80
3,116.00
2,711.10
2,283.80
1,421.50

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
913.40
838.40
582.20
698.00
677.40
629.80
445.60
398.10
308.10
18.50
PBT
557.30
600.90
481.70
467.40
515.70
330.70
305.10
287.30
240.80
203.50
Adjustment
289.20
375.30
381.30
278.60
223.20
212.50
248.10
148.40
132.90
72.90
Changes in Working Capital
165.30
-4.10
-176.60
34.80
44.90
182.30
-26.80
36.90
-25.50
-215.80
Cash after chg. in Working capital
1,011.80
972.10
686.40
780.80
783.80
725.50
526.40
472.60
348.20
60.60
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-98.40
-133.70
-104.20
-82.80
-106.40
-95.70
-80.80
-74.50
-40.10
-42.10
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-383.50
-688.20
-611.50
-628.10
-428.40
-646.50
-349.60
-469.10
-751.20
12.00
Net Fixed Assets
-933.50
109.10
-587.30
-440.10
-806.60
-578.80
-309.30
-158.60
-305.10
-277.90
Net Investments
13.20
93.60
-294.50
72.80
-56.40
-598.30
382.40
-263.80
-130.60
206.10
Others
536.80
-890.90
270.30
-260.80
434.60
530.60
-422.70
-46.70
-315.50
83.80
Cash from Financing Activity
-536.30
-340.20
-31.30
58.00
-225.50
-72.40
-78.70
-81.20
716.10
-10.10
Net Cash Inflow / Outflow
-6.40
-190.00
-60.60
127.90
23.50
-89.10
17.30
-152.20
273.00
20.40
Opening Cash & Equivalents
72.10
259.00
318.90
191.80
163.70
251.80
234.50
387.30
115.70
91.60
Closing Cash & Equivalent
66.60
72.10
259.00
318.90
191.80
163.70
251.80
234.50
387.30
115.70

Financial Ratios

Standalone /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
103.83
88.59
79.97
68.53
53.38
48.48
42.30
34.70
25.14
20.92
ROA
8.08%
8.40%
7.66%
9.15%
10.76%
9.83%
10.47%
11.50%
13.00%
13.40%
ROE
12.07%
13.99%
13.24%
16.56%
20.20%
18.21%
19.81%
24.00%
26.19%
23.55%
ROCE
13.76%
15.61%
13.19%
15.35%
19.57%
16.94%
16.70%
17.60%
19.85%
23.31%
Fixed Asset Turnover
0.77
0.81
0.71
0.68
0.79
0.97
0.95
0.98
1.08
1.04
Receivable days
51.89
56.66
68.93
73.07
66.84
60.53
59.70
58.34
60.19
58.19
Inventory Days
32.26
29.24
16.77
7.10
6.22
12.94
15.16
10.62
12.55
11.31
Payable days
1658.62
-2153.93
-4008.24
160.11
54.64
59.61
54.99
38.31
36.00
45.79
Cash Conversion Cycle
-1574.47
2239.83
4093.94
-79.94
18.42
13.85
19.87
30.65
36.74
23.72
Total Debt/Equity
0.03
0.16
0.25
0.28
0.32
0.41
0.47
0.58
0.89
0.19
Interest Cover
19.89
14.29
20.99
17.87
15.90
13.82
17.39
20.80
34.45
26.76

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Syngene International to make additional investment in Syngene USA Inc
    11th Mar 2025, 12:12 PM

    The investment is expected to be completed on or before March 31, 2026 or such other date mutually agreed between the parties

    Read More
  • Syngene International’s arm acquires first biologics site in USA
    11th Mar 2025, 11:23 AM

    The new site will increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services

    Read More
  • USFDA concludes pre-approval, cGMP inspection at Bengaluru facilities of Syngene International
    24th Feb 2025, 10:06 AM

    The inspection conducted from February 10, 2025 to February 20, 2025

    Read More
  • Syngene Internation. - Quarterly Results
    23rd Jan 2025, 15:06 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.